SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism

SGLT2 Inhibitor Treatment Is Associated With Reduced Cardiac Glucose Metabolism

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have cardioprotective effects without acting directly on the myocardium. Objectives: The purpose of the study was to evaluate the impact of SGLT2i on myocardial glucose utilization. Methods: This retrospective propensity-matched cohort...

Full description

Saved in:
Bibliographic Details
Main Authors: Brett W. Sperry, MD, Yazan Almohtasib, MD, Ramy Ghaly, MD, Mohammad Abdel Jawad, MD, Andrew J. Sauer, MD, Timothy M. Bateman, MD
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JACC: Advances
Subjects:
cardiomyopathy
diabetes
fatty acids
heart failure
ketone body
metabolic syndrome
Online Access:http://www.sciencedirect.com/science/article/pii/S2772963X25004405
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2772963X25004405

Similar Items